ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALXO vs SION // DIVIDEND YIELD & FCF PAYOUT SAFETY

ALX Oncology Holdings Inc. (NASDAQ) VS. Sionna Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALXO 3 — SION 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALXO VS. SION) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALXO SION SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.30% -6.70 SION /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ALXO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.4 32.0 +24.40 ALXO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $171.1M $168.6M $2.5M ALXO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALXO REV SION REV ALXO GROSS % SION GROSS % ALXO FCF SION FCF
FY 2025 $291.3M $249.1M — — -$84.4M -$66.7M
FY 2024 $398.9M $197.6M — — -$122.4M -$52.8M
FY 2023 $476.8M — — — -$130.4M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALXO // BETA —
SION // BETA —